Our Team

Dr. Jan Claas-von Jachmann has more than 25 years of experience in Biotech & Pharma industry covering a broad spectrum from Pre-clinical Research to Head of International Marketing and General Management. He was responsible for the commercial development and successful launch of innovations on a national & international level and for the leadership of complex organizations with proven success. His international experience is based on 10 years in European Managing Director roles and the collaboration with global players over many years. In addition, he supported Start-up businesses in mentoring and coaching roles in recent years. Dr. Jan Claas-von Jachmann joined PROVIREX on March 1st 2025 as Chief Executive Officer and Partner.

Oliver Ahnfeld is a co-founder of PROVIREX. He has been one of the CEOs of the company since its inception in 2019, and has focused on its entrepreneurial transformation into a biotech company. He has been part of the team for more than 8 years and is responsible for the financial/contractual aspects and the strategic direction of PROVIREX. He studied industrial engineering in Hamburg and has several years of experience in preparing business and financial plans as well as accompanying private placements.

Dr. Jan Chemnitz is a co-founder of PROVIREX. Since its inception, he has been one of the company’s CEOs and has focused on its transition from start-up to a Series A funded biotech company. He is also responsible for building up a collaborative network with other biotech companies as well as academia and implementing the ongoing academic clinical study “HIVCure” into the company’s future strategy.

He studied biochemistry/molecular biology in Jena. After his PhD at the Leibniz Institute of Virology in Hamburg, he joined the Hauber group as a postdoc and was involved in the development of the recombinase technology from the beginning; he has now been working in the field of HIV cure strategies for 20 years.

Dr. Maike Voges is a co-founder of PROVIREX. She participates in the active management of the company and, together with experts, leads the introduction of a quality management system, supervises the construction and installation of new laboratories and clean rooms, and implements the quality standards at PROVIREX.

She studied biology in Tübingen, focusing on microbiology, virology and immunology, which she intensified during her PhD at the University of Constance and subsequently at the Leibniz Institute of Virology in Hamburg in the group of Prof. Dr. Joachim Hauber. In between, she worked in the quality control department of a smaller pharmaceutical company and later successfully completed additional training as a clinical monitor. She has been part of the team for more than 10 years.

Dr. Niklas Beschorner is Chief Technology Officer (CTO) and co-founder of PROVIREX. He is responsible for ATMP manufacturing and R&D, driving the development of enabling technologies, translational processes, and novel delivery approaches for recombinase-based therapies. He brings deep scientific and operational expertise in HIV cure research and the advancement of innovative antiviral treatment strategies.